Supernus Pharmaceuticals (SUPN) Q3 2026 earnings summary

Executive summary

• Record Q3 revenue was $226.8M, up 18% YoY; four growth products generated $192.2M, up 29%.

• Growth in Qelbree, ONAPGO and ZURZUVAE offset declines in legacy products; Indivior merger closing was expected Nov. 2, 2026.

Financial highlights

• Q3 revenue was $226.8M versus $192.1M; 9M revenue was $653.5M versus $507.4M.

• Q3 revenue comprised $178.6M product sales, $41.7M ZURZUVAE collaboration revenue and $6.5M royalties, licensing and other revenue.

• Q3 total revenue excluding Trokendi XR and Oxtellar XR was $208.6M, up 23%; 9M total was $601.2M, up 37%.

• Q3 commercial product revenue was $220.3M, up 17%; 9M total was $599.7M, up 23%.

• 9M net loss was $39.8M versus $34.4M; 2026 included $56.5M in impairment charges, primarily for APOKYN.

Outlook and guidance

• Raised standalone FY 2026 revenue guidance to $875M–$900M from $860M–$890M; adjusted operating earnings guidance rose to $160M–$180M from $150M–$180M.

• FY 2026 GAAP operating loss guidance improved to $5M–$40M from $20M–$50M; guidance included ONAPGO sales of $60M–$65M and Trokendi XR/Oxtellar XR sales of $60M–$67M.

• Standalone guidance ceases to apply if the merger closes; combined FY 2027 guidance was expected in February 2027.

• Management expected future profitability, while noting variability from market pressures, patent erosion, R&D and commercial launch spending.